Controller, Former Interim Chief Financial Officer · Niagen Bioscience, Inc. (NAGE)

James Lee

FY2024 is the first fiscal year CompBrief holds for James Lee as a named executive officer of Niagen Bioscience; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2024

$374,470

Salary $228,462Stock awards $0

4th of 5 named executive officers at Niagen Bioscience by FY2024 total.

5 named officers on file for Niagen Bioscience, FY2024

James Lee’s pay file — $29

  • 1 fiscal year of pay, line by line
  • 1 equity grant, each cited to its filing

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Niagen Bioscience’s whole pay program stands against its peers

  • Niagen Bioscience’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on NAGE→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 29, 2025 (DEF 14A).

Free

Get James Lee’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

James Lee compensation by year

Niagen Bioscience Summary Compensation Table · the one fiscal year held
In US dollars, as Niagen Bioscience reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2024
Salary$228,462
Bonus$0
Stock awards$0
Option awards$87,979
Non-equity incentive$49,433
Pension and deferred compensation$0
All other$8,596
Total$374,470

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Niagen Bioscience, Inc. DEF 14A filed April 29, 2025, accession 0001628280-25-020690, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Niagen Bioscience, Inc. filed document, accession 0001628280-25-020690. Every figure is read from that document and cited to the page and table it appears in. Filed April 29, 2025.

Equity holdings

unvested awards at FY2024 year-end
TypeUnvested unitsValue at year-endExercise price
Option2,346—$2.67
Option22,594—$1.82
Option82,734—$1.52

Per the Outstanding Equity Awards at Fiscal Year-End table in Niagen Bioscience, Inc.'s FY2024 proxy; value at the fiscal year-end close, as the company printed it.

Niagen Bioscience’s named executive officers, FY2024

as the company reported each
Named executive officerRoleFY2024 total
Robert FriedChief Executive Officer$1,212,131
Ozan PamirChief Financial Officer$461,641
Brianna GerberFormer Chief Financial Officer$450,969
James Lee · this pageController, Former Interim Chief Financial Officer$374,470
Carlos LopezSenior Vice President, General Counsel$347,637

The full Niagen Bioscience compensation record

free company brief

This page is one person within Niagen Bioscience's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Niagen Bioscience's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

James Lee's compensation dossier · One-time report. No refunds.